Total Payments
$1,074
2023 Payments
$19.01
Companies
20
Transactions
74
Medicare Patients
2,246
Medicare Billing
$255,101
Payment Breakdown by Category
Food & Beverage$1,074 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,074 | 74 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie Inc. | $265.91 | 22 | $0 (2023) |
| Novo Nordisk Inc | $158.21 | 11 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $141.22 | 7 | $0 (2022) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $99.93 | 7 | $0 (2022) |
| Amgen Inc. | $77.97 | 5 | $0 (2022) |
| Astellas Pharma US Inc | $64.95 | 4 | $0 (2021) |
| Daiichi Sankyo Inc. | $43.80 | 2 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $32.25 | 2 | $0 (2021) |
| Allergan, Inc. | $29.72 | 2 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $26.59 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $19.01 | 1 | AbbVie Inc. ($19.01) |
| 2022 | $89.23 | 6 | ABBVIE INC. ($27.06) |
| 2021 | $796.39 | 55 | AbbVie Inc. ($207.28) |
| 2020 | $139.29 | 10 | Novo Nordisk Inc ($24.14) |
| 2019 | $29.83 | 2 | Allergan Inc. ($15.35) |
All Payment Transactions
74 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/27/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: NEUROSCIENCE | ||||||
| 05/15/2022 | Medtronic, Inc. | INTELLIS ADAPTIVESTIM (Device) | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: Spinal Cord Neurostimulation | ||||||
| 03/04/2022 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $13.75 | General |
| Category: NEUROSCIENCE | ||||||
| 03/02/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: Gastroenterology | ||||||
| 02/02/2022 | Amgen Inc. | Aimovig (Biological), Otezla, Repatha | Food and Beverage | In-kind items and services | $13.60 | General |
| Category: Neuroscience | ||||||
| 01/07/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: NEUROSCIENCE | ||||||
| 01/04/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.88 | General |
| Category: NEUROSCIENCE | ||||||
| 12/15/2021 | Novo Nordisk Inc | RYBELSUS (Drug), Ozempic | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: Diabetes | ||||||
| 12/13/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $12.76 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 12/10/2021 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $15.10 | General |
| Category: Neuroscience | ||||||
| 12/07/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV | Food and Beverage | In-kind items and services | $18.95 | General |
| 11/18/2021 | AbbVie Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/18/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $3.70 | General |
| Category: NEUROSCIENCE | ||||||
| 11/16/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $13.83 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 11/16/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.09 | General |
| Category: NEUROSCIENCE | ||||||
| 11/15/2021 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $24.83 | General |
| Category: NEUROSCIENCE | ||||||
| 11/11/2021 | AbbVie Inc. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $14.34 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/10/2021 | Novo Nordisk Inc | RYBELSUS (Drug), Ozempic | Food and Beverage | In-kind items and services | $15.31 | General |
| Category: Diabetes | ||||||
| 11/05/2021 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $14.82 | General |
| Category: NEUROSCIENCE | ||||||
| 11/02/2021 | Novo Nordisk Inc | RYBELSUS (Drug), Ozempic | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: Diabetes | ||||||
| 10/27/2021 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: NEUROSCIENCE | ||||||
| 10/21/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.71 | General |
| Category: NEUROSCIENCE | ||||||
| 10/19/2021 | Nestle HealthCare Nutrition Inc. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $13.32 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 10/19/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $11.41 | General |
| Category: Diabetes | ||||||
| 10/14/2021 | Novo Nordisk Inc | RYBELSUS (Drug), Ozempic | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 350 | 475 | $100,518 | $36,019 |
| 2022 | 8 | 206 | 286 | $58,898 | $18,566 |
| 2021 | 14 | 585 | 780 | $147,277 | $69,270 |
| 2020 | 19 | 1,105 | 1,637 | $207,640 | $131,245 |
Total Patients
2,246
Total Services
3,178
Medicare Billing
$255,101
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 99 | 180 | $29,978 | $11,089 | 37.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 91 | 92 | $22,008 | $8,102 | 36.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 30 | 43 | $10,234 | $3,919 | 38.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 40 | 40 | $12,574 | $3,883 | 30.9% |
| 99305 | Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | Facility | 2023 | 23 | 24 | $6,960 | $2,499 | 35.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Office | 2023 | 22 | 22 | $5,258 | $1,971 | 37.5% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 20 | 46 | $4,240 | $1,792 | 42.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 14 | 14 | $6,480 | $1,665 | 25.7% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 11 | 14 | $2,786 | $1,100 | 39.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 50 | 93 | $15,452 | $5,181 | 33.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Office | 2022 | 42 | 42 | $10,038 | $3,446 | 34.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 22 | 34 | $8,092 | $2,722 | 33.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 35 | 47 | $12,154 | $2,598 | 21.4% |
| 99217 | Hospital observation care on day of discharge | Office | 2022 | 22 | 22 | $3,608 | $1,228 | 34.0% |
| 99225 | Follow-up observation care per day, typically 25 minutes | Office | 2022 | 12 | 21 | $2,667 | $1,164 | 43.7% |
| 99309 | Follow-up nursing facility visit per day, typically 25 minutes | Facility | 2022 | 12 | 16 | $3,472 | $1,127 | 32.5% |
| 99305 | Initial nursing facility visit per day, typically 35 minutes | Facility | 2022 | 11 | 11 | $3,415 | $1,101 | 32.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 206 | 311 | $57,340 | $25,808 | 45.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 97 | 146 | $30,723 | $16,486 | 53.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 68 | 68 | $12,246 | $8,425 | 68.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 40 | 40 | $15,032 | $4,548 | 30.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 20 | 20 | $8,283 | $3,107 | 37.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 37 | 39 | $4,993 | $2,586 | 51.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 14 | 15 | $4,179 | $2,288 | 54.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 12 | 29 | $4,711 | $2,283 | 48.5% |
About Dr. Jennie Stanford, M.D
Dr. Jennie Stanford, M.D is a Medical Specialty healthcare provider based in New Canaan, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/11/2016. The National Provider Identifier (NPI) number assigned to this provider is 1588028153.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jennie Stanford, M.D has received a total of $1,074 in payments from pharmaceutical and medical device companies, with $19.01 received in 2023. These payments were reported across 74 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($1,074).
As a Medicare-enrolled provider, Stanford has provided services to 2,246 Medicare beneficiaries, totaling 3,178 services with total Medicare billing of $255,101. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Specialty
- Other Specialties Medical Specialty, Clinic/Center
- Location New Canaan, CT
- Active Since 04/11/2016
- Last Updated 07/16/2024
- Taxonomy Code 261QM2500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1588028153
Products in Payments
- TRINTELLIX (Drug) $141.22
- VRAYLAR (Drug) $124.93
- XIFAXAN (Drug) $99.93
- UBRELVY (Drug) $86.20
- RYBELSUS (Drug) $83.08
- Ozempic (Drug) $75.13
- Aimovig (Biological) $65.30
- MYRBETRIQ (Drug) $64.95
- INJECTAFER (Drug) $43.80
- LINZESS (Drug) $42.94
- QULIPTA (Drug) $29.00
- XARELTO (Drug) $26.59
- INTELLIS ADAPTIVESTIM (Device) $18.76
- NURTEC ODT (Drug) $15.25
- BELSOMRA (Drug) $13.83
- ZENPEP (Drug) $13.32
- JARDIANCE (Drug) $13.30
- TROKENDI XR (Drug) $13.25
- EVENITY (Biological) $12.67
- HUMIRA (Biological) $12.56
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.